These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18702737)

  • 1. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression.
    Lemke MR
    Eur J Neurol; 2008 Sep; 15 Suppl 2():9-14. PubMed ID: 18702737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor agonists and depression in Parkinson's disease.
    Picillo M; Rocco M; Barone P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S81-4. PubMed ID: 20123564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.
    Leentjens AF
    Drugs; 2011 Feb; 71(3):273-86. PubMed ID: 21319866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease.
    Rektorová I
    Neurodegener Dis; 2010; 7(1-3):206-9. PubMed ID: 20224287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical treatment of Parkinson's disease].
    Waldvogel D
    Ther Umsch; 2007 Jan; 64(1):15-20. PubMed ID: 17221820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment.
    Dogan B; Akyol A; Memis CO; Sair A; Akyildiz U; Sevincok L
    Psychogeriatrics; 2019 Jan; 19(1):73-79. PubMed ID: 30141277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of antidepressant medication in Parkinson's disease patients is not affected by the type of antiparkinson medication.
    Krøigård T; Christensen J; Wermuth L; Ritz B; Lassen CF
    J Parkinsons Dis; 2014; 4(3):327-30. PubMed ID: 24919822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
    Raskin S; Durst R
    Med Hypotheses; 2010 Dec; 75(6):544-6. PubMed ID: 20708340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment.
    Valko PO; Waldvogel D; Weller M; Bassetti CL; Held U; Baumann CR
    Eur J Neurol; 2010 Dec; 17(12):1428-36. PubMed ID: 20491889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of dopamine receptor agonists in the treatment of depression in patients with Parkinson's disease].
    Fedorova NV; Miretskaia AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(12):87-92. PubMed ID: 20178161
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relevance of dopamine agonists in the treatment of depression].
    Clausius N; Born C; Grunze H
    Neuropsychiatr; 2009; 23(1):15-25. PubMed ID: 19272288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2005 Jan; 12(1):9-15. PubMed ID: 15613141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine agonists in the future--clinical trials of new medications].
    Jasińska-Myga B; Opala G
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S49-53. PubMed ID: 17941459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.